Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lilian M Pereira Palma & Craig B Langman. (2016) Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. Journal of Blood Medicine 7, pages 39-72.
Read now
Read now
Articles from other publishers (21)
Lena J. Heung, Darin L. Wiesner, Keyi Wang, Amariliz Rivera & Tobias M. Hohl. (2023) Immunity to fungi in the lung. Seminars in Immunology 66, pages 101728.
Crossref
Crossref
Hariharan Regunath, Kyle Ludwig & Ramesh Khanna. 2020. Nolph and Gokal's Textbook of Peritoneal Dialysis. Nolph and Gokal's Textbook of Peritoneal Dialysis
1
35
.
Hariharan Regunath, Kyle Ludwig & Ramesh Khanna. 2023. Nolph and Gokal's Textbook of Peritoneal Dialysis. Nolph and Gokal's Textbook of Peritoneal Dialysis
431
465
.
Nehemiah T. Zewde, Rohaine V. Hsu, Dimitrios Morikis & Giulia Palermo. (2021) Systems Biology Modeling of the Complement System Under Immune Susceptible Pathogens. Frontiers in Physics 9.
Crossref
Crossref
Hariharan Regunath, Kyle Ludwig & Ramesh Khanna. 2020. Nolph and Gokal's Textbook of Peritoneal Dialysis. Nolph and Gokal's Textbook of Peritoneal Dialysis
1
34
.
J. Dotis, A. Kondou, E. Koukloumperi, V. Karava, A. Papadopoulou, C. Gkogka & N. Printza. (2020) Aspergillus peritonitis in peritoneal dialysis patients: A systematic review. Journal de Mycologie Médicale 30:4, pages 101037.
Crossref
Crossref
Katrin Giglhuber & Achim Berthele. (2020) Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 12:14, pages 1053-1066.
Crossref
Crossref
Esther Benamu. (2020) Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infectious Disease Clinics of North America 34:2, pages 271-310.
Crossref
Crossref
Luis Malpica, David Duin & Stephan Moll. (2019) Preventing infectious complications when treating non‐malignant immune‐mediated hematologic disorders. American Journal of Hematology 94:12, pages 1396-1412.
Crossref
Crossref
H. Han, S. Alagusundaramoorthy, K. Swanson, A.I. Gardezi & M.R. Chan. (2019)
Acute
Candida albicans
Peritonitis in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab
. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 39:6, pages 575-576.
Crossref
Crossref
Eric Rondeau, Spero R. Cataland, Imad Al-Dakkak, Benjamin Miller, Nicholas J.A. Webb & Daniel Landau. (2019) Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney International Reports 4:11, pages 1568-1576.
Crossref
Crossref
Kate Smith-Jackson, Yi Yang, Harriet Denton, Isabel Y. Pappworth, Katie Cooke, Paul N. Barlow, John P. Atkinson, M. Kathryn Liszewski, Matthew C. Pickering, David Kavanagh, H. Terence Cook & Kevin J. Marchbank. (2019) Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. Journal of Clinical Investigation 129:3, pages 1061-1075.
Crossref
Crossref
Page E. Crew, Lucy McNamara, Peter E. Waldron, Lynda McCulley, S. Christopher Jones & Susan J. Bersoff-Matcha. (2019) Unusual Neisseria species as a cause of infection in patients taking eculizumab. Journal of Infection 78:2, pages 113-118.
Crossref
Crossref
Megan ClancyRyan McGhanJeremy GitomerAna Marie InocencioChristina AldrichRoberto IaderosaRyan Stevens. (2018) Disseminated cryptococcosis associated with administration of eculizumab. American Journal of Health-System Pharmacy 75:14, pages 1018-1022.
Crossref
Crossref
K.L. Winthrop, X. Mariette, J.T. Silva, E. Benamu, L.H. Calabrese, A. Dumusc, J.S. Smolen, J.M. Aguado & M. Fernández-Ruiz. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clinical Microbiology and Infection 24, pages S21-S40.
Crossref
Crossref
Toru Kawakami, Hideyuki Nakazawa, Yukifumi Kurasawa, Hitoshi Sakai, Sayaka Nishina, Noriko Senoo, Yasushi Senoo & Fumihiro Ishida. (2018) Severe Infection of <i>Pseudomonas aeruginosa</i> during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. Internal Medicine 57:1, pages 127-130.
Crossref
Crossref
Luis Gustavo Modelli de Andrade, Mariana Moraes Contti, Hong Si Nga, Ariane Moyses Bravin, Henrique Mochida Takase, Rosa Marlene Viero, Trycia Nunes da Silva, Kelem De Nardi Chagas & Lilian Monteiro Pereira Palma. (2017) Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLOS ONE 12:11, pages e0188155.
Crossref
Crossref
Enora Atchade, Sylvain Jean-Baptiste, Sandrine Houzé, Claire Chabut, Laurent Massias, Yves Castier, Olivier Brugière, Hervé Mal & Philippe Montravers. (2017) Fatal invasive aspergillosis caused by Aspergillus niger after bilateral lung transplantation. Medical Mycology Case Reports 17, pages 4-7.
Crossref
Crossref
Yeoungjee Cho & Dirk Gijsbert Struijk. (2017) Peritoneal Dialysis–Related Peritonitis: Atypical and Resistant Organisms. Seminars in Nephrology 37:1, pages 66-76.
Crossref
Crossref
Esther Benamu & José G. Montoya. (2016) Infections associated with the use of eculizumab. Current Opinion in Infectious Diseases 29:4, pages 319-329.
Crossref
Crossref
. (2015) Eculizumab. Reactions Weekly 1536:1, pages 91-91.
Crossref
Crossref